CHANGES OF CYTOKINE LEVELS DURING THERAPY WITH METHOTREXATE AND ADALIMUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS (REMARCA STUDY)
https://doi.org/10.14412/1995-4484-2014-254-262
Abstract
Objective: to estimate changes in cytokine profile versus disease activity in patients with early rheumatoid arthritis (RA) who use methotrexate (MTX) and adalimumab (ADA) in accordance with the treat-to-target concept. Subjects and methods. Forty-five patients (35 women; median age 53.5 [46; 59.5] years) with early RA (median dura- tion 7.0 [4.0; 11.5] months; DAS28 5.8 [4.9; 6.4]; rheumatoid factor positivity (RF+) 91%; anti-cyclic citrullinated peptide antibody positivity (ACCP) + 96%) were examined. In all the patients, MTX as the first agent was subcuta- neously used in a dose of 10 mg/week with its rapid escalation up to 20-25 mg/week. Serum cytokine concentrations were determined using the xMAP multiplexing technology before and 12 and 24 weeks after therapy.
Results. Following 12 weeks of therapy, DAS28 mean value decreased to 4.33 [3.5; 5.2] (p < 0.05 vs baseline). Twenty- nine (64.4%) patients responded to treatment. It was decided to continue MTX monotherapy in 23 patients (a monotherapy group) and in 22 patients ADA was added to therapy due to its inadequate effect in accordance with the standard regimen (a combined therapy group). At 24 weeks, mean DAS28 was 2.9 [2.1; 3.6] and 19 (82.6%) patients responded to treatment in the monotherapy group. In the combined therapy group, DAS28 was 3.4 [3.2; 4.4]; nearly 30% of the patients achieved remission/low disease activity and the number of patients with the high activity of a pathological process also declined significantly (from 59.1 to 13.6%).
At 12 weeks, the monotherapy group showed reduction of the level of proinflammatory (interleukin-6 (IL-6), IL-17, tumor necrosis factor-α (TNF-α)), anti-inflammatory (IL-4, IL-5, IL-9, IL-13) cytokines, chemokines (interferon induced protein-10 (IP-10)), and vascular endothelial growth factors (VEGF) (p<0.05); at 24 weeks, there were reductions in IL-6, IL-9, and IL-10, and transforming GF-bb and an increase in IL-10 concentration (p<0.05).
At 12 weeks of MTX therapy, the combined therapy group displayed a reduction in IL-6, IL-1Pa, IP-10 (p<0.05); at 24 weeks of treatment (12-week ADA administration) there were decreases in proinflammatory (IL-12), anti-inflammatory (IL-9) cytokines, chemokines (IP-10, monocyte chemoattractant protein, and macrophageal inflammatory protein-1β), VEGF and an elevation of IL-10. Conclusion. Thus, the results of the investigation suggest the high clinical efficiency of therapy with subcutaneous MTX, which is associated with the lower levels of a number of proinflammatory cytokines, chemokines, and growth factors. ADA treatment is also accompanied by decreased disease activity and positive changes in the cytokine profile, by exerting a higher impact on the level of chemokines and growth factors.
About the Authors
A. S. Avdeeva
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
A. A. Novikov
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
E. N. Aleksandrova
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
D. E. Karateev
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
E. L. Luchikhina
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
E. L. Nasonov
Nasonova Research Institute of Rheumatology, Moscow, Russia
Russian Federation
Russian Federation
References
1. Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР- Медиа; 2008. С. 290–331. [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Revmatologiya. Natsional’noe rukovodstvo [Rheumatology. National Guide]. Nasonov EL, Nasonova VA, editors. Moscow: GEOTAR-media; 2008. P. 290–331.]
2. Ревматология. Клинические рекомендации. Под ред. Е.Л. Насонова. Москва: ГЭОТАР-Медиа; 2010. [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical recommendations]. Moscow: GEOTAR-media; 2010.]
3. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommen- dations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75. DOI: 10.1136/ard.2009.126532. Epub 2010 May 5.
4. Rantalaiho V, Korpela M, Laasonen L, et al.; FIN-RACo Trial
5. Group. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12(3):R122. DOI: 10.1186/ar3060. Epub 2010 Jun 24.
6. Landewe RB, Boers M, Verhoeven AC, et al. COBRA combina- tion therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46(2):347–56. DOI: http://dx.doi.org/10.1002/art.10083.
7. Smolen J, Aletaha D, Bijsma JW, et al. for the T2T Exspert Committee. Treating rheumatoid arthritis to target: recommenda- tions of an international task force. Ann Rheum Dis. 2010;69(4):631–7. DOI: 10.1136/ard.2009.123919. Epub 2010 Mar 9.
8. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomesed controlled trial. Lancet. 2004;364(9430):263–9. DOI: http://dx.doi.org/10.1016/S0140- 6736(04)16676-2.
9. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treat- ment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007 Nov;66(11):1443–9. DOI: http://dx.doi.org/10.1136/ard.2007.071092. Epub 2007 May 22.
10. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent- onset active rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):65–9. DOI: 10.1136/ard.2008.097683.
11. Schipper LG, Vermeer M, Kuper HH, et al. A tight control treat- ment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis. 2012;71(6):845–50. DOI: 10.1136/annrheumdis-2011-200274. Epub 2011 Dec 30.
12. Choy E. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(3):510–8.
13. Firestein G. Evolving concepts of rheumatoid arthritis. Nature. 2003;344(6937):907–16.
14. McInnes IB, Schett G. Cytokines in the pathogenesis of rheuma- toid arthritis. Nat Rev Immunol. 2007;7(6):429–42. DOI: http://dx.doi.org/10.1038/nri2094.
15. Dayer J, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985;162(6):2163–8. DOI: http://dx.doi.org/10.1084/jem.162.6.2163.
16. Bazzoni F, Beutler B. The tumor necrosis factor ligand and recep- tor families. N Engl J Med. 1996;334(26):1717–25. DOI: http://dx.doi.org/10.1056/NEJM199606273342607.
17. Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology of tumor necrosis factor-alpha-implications for psoriasis. Exp Dermatol. 2004;13(4):193–222. DOI: http://dx.doi.org/10.1111/j.0906-6705.2004.00205.x.
18. Victor FC, Gottlieb AB, Menter A. Changing paradigms in der- matology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol. 2003 Sep- Oct;21(5):392–7. DOI: http://dx.doi.org/10.1016/j.clinderma- tol.2003.08.015.
19. Taha A, Grant V, Kelly R. Urinalysis for interleukin-8 in the non- invasive diagnosis of acute and chronic inflammatory diseases. Postgrad Med J. 2003;79(929):159–63. DOI: http://dx.doi.org/10.1136/pmj.79.929.159.
20. Rothe L, Collin-Osdoby P, Chen Y, et al. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8.
21. Endocrinology. 1998;139(10):4353–63.
22. Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its solu-
23. ble receptor in induction of chemokines and leukocyte recruit- ment. Immunity. 1997;6(3):315–25. DOI: http://dx.doi.org/10.1016/S1074-7613(00)80334-9.
24. Lally F, Smith E, Filer A, et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum. 2005;52(11):3460–9. DOI: http://dx.doi.org/10.1002/art.21394.
25. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treat- ment of rheumatoid arthritis. Lancet. 2007;370(9602):1861–74. DOI: http://dx.doi.org/10.1016/S0140-6736(07)60784-3.
26. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res. 2002;4 Suppl 3:S81–90. DOI: http://dx.doi.org/10.1186/ar575. Epub 2002 May 9.
27. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther. 2007;9(1):203. DOI: http://dx.doi.org/10.1186/ar2110.
28. Kudo O, Sabokbar A, Pocock A, et al. Interleukin-6 and inter- leukin-11 support human osteoclast formation by a RANKL-inde- pendent mechanism. Bone. 2003;32(1):1–7. DOI: http://dx.doi.org/10.1016/S8756-3282(02)00915-8.
29. Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 recep- tor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48(6):1521–9. DOI: http://dx.doi.org/10.1002/art.11143.
30. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49(1):15–24. DOI: 10.1093/rheumatology/kep329. Epub 2009 Oct 23.
31. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regu- latory T cells. Nature. 2006;441(7090):235–8. DOI: http://dx.doi.org/10.1038/nature04753. Epub 2006 Apr 30.
32. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85(3):307–10. DOI: http://dx.doi.org/10.1016/S0092- 8674(00)81109-5.
33. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. DOI: http://dx.doi.org/10.1146/annurev.immunol.14.1.397.
34. Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51(2):117–25. [Karateev DE, Luchikhina EL, Muravyev YuV, et al. The first Russian strategic study of phar- macotherapy for rheumatoid arthritis (REMARCA). Nauchno- prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):117–25. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2013-637.
35. Fransen J, Stucki G, van Reil PLCM. Rheumatoid arthritis meas- ures. Arthritis Rheum. 2003;49:214–24. DOI: http://dx.doi.org/10.1002/art.11407.
36. Aletaha D, Nell V, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: vali- dation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796–806. DOI: http://dx.doi.org/10.1186/ar1740. Epub 2005 Apr 7.
37. Katchamart W, Trudeau J, Phumethum V, et al. Efficacy and toxi- city of methotrexate (MTX) monotherapy versus MTX combina- tion therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analy- sis. Ann Rheum Dis. 2009;68(7):1105–12. DOI: 10.1136/ard.2008.099861. Epub 2008 Dec 3.
38. Gaujoux-Viala C, Smolen JS, Landewe R, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):1004–9. DOI: 10.1136/ard.2009.127225. Epub 2010 May 6.
39. Gaujoux-Viala C, Nam JL, Ramiro S, et al. Efficacy of conven-
40. tional synthetic disease-modifying antirheumatic drugs, glucocor- ticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):510–5. DOI: 10.1136/annrheumdis-2013-204588. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-204588. Epub 2014 Jan 6.
41. Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a Threat-to-Target Strategy in very Early Rheumatoid Arthritis. Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort Study. Arthritis Rheum. 2011;63(10):2865–72. DOI: 10.1002/art.30494.
42. Vermeer M, Kuper HH, Bernelot Moens HJ, et al. Sustained beneficial effects of a protocolized Ttreat-to-Target strategy in very early rheumatoid arthritis: three-year results of the Dutch rheumatoid arthritis monitoring remission induction cohort. Arthritis Care Res (Hoboken). 2013;65(8):1219–26. DOI: 10.1992/acr.21984.
43. Bosello S, Fedele AL, Peluso G, et al. Very early rheumatoid arthritis is the major predictor of major outcome: clinical ACR remission and radiographic non-progression. Ann Rheum Dis. 2011;70(7):1292–5. DOI: 10.1136/ard.2010.142729. Epub 2011 Apr 22.
44. Dolhain RJ, Tak PP, Dijkmans BA, et al. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhe- sion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol. 1998;37(5):502–8. DOI: http://dx.doi.org/10.1093/rheumatology/37.5.502.
45. Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflamma- tion and metalloproteinase expression in synovial tissue by lefluno- mide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel- design clinical trial in thirty-nine patients at two centers. Arthritis Rheum. 2000;43(8):1820–30. DOI: http://dx.doi.org/10.1002/1529- 0131(200008)43:8%3C1820::AID-ANR18%3E3.0.CO;2-D.
46. Barrera P, Boerbooms AM, Demacker PN, et al. Circulating con- centrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate. Br J Rheumatol. 1994;33(11):1017–24. DOI: http://dx.doi.org/10.1093/rheumatology/33.11.1017.
47. Seitz M, Loetscher P, Dewald B, et al. Interleukin 1 (IL-1) recep- tor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8-markers of remission in rheumatoid arthritis during treatment with methotrexate. J Rheumatol. 1996;23(9):1512–6.
48. Swaak AJ, van den Brink HG, Aarden LA. Cytokine production in whole blood cell cultures of patients with rheumatoid arthritis. Ann Rheum Dis. 1997;56(11):693–5. DOI: http://dx.doi.org/10.1136/ard.56.11.693.
49. Rudwaleit M, Yin Z, Siegert S, et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis. 2000;59(4):311–4. DOI: http://dx.doi.org/10.1136/ard.59.4.311.
50. Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol. 2001;167(5):2911–20. DOI: http://dx.doi.org/10.4049/jimmunol.167.5.2911.
51. Gerards A, de Lathouder S, de Groot E, et al. Inhibition of cytokine production by methotrexate. Rheumatology (Oxford). 2003;42(10):1189–96. DOI: http://dx.doi.org/10.1093/rheumatol- ogy/keg323. Epub 2003 May 30.
52. Yellin M, Paliienko I, Balanescu A, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of mdx-1100, a fully human anti-cxcl10 monoclonal anti- body, in combination with methotrexate in patients with rheuma- toid arthritis. Arthritis Rheum. 2012;64(6):1730–39. DOI: 10.1002/art.34330. Epub 2011 Dec 6.
53. Boyle D, Wei N, Singhal A. The Jak inihibitor Tofacitinib sup- presses synovial Jak-stat signalling in rheumatoid arthritis. Arthritis Rheum. 2013; 65(Suppl):764.
54. Yamana J, Iwahashi M, Kim M, et al. T-cell-related cytokines are inhibited in response to tocilizumab in patients with rheumatoid arthritis in contrast with TNF inhibitor. Arthritis Rheum. 2011;63(Suppl):18.
55. Knudsen LS, Hetland ML, Johansen JS, et al. Changes in plasma IL-6, plasma VEGF and serum YKL-40 during treatment with Etanercept and Methotrexate or Etanercept alone in patients with active rheumatoid arthritis despite Methotrexate therapy. Biomark Insights. 2009;4:91–5.
56. Ducreux О, Durez P, Galant C, et al. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheum. 2014;66(1):15–23. DOI: 10.1002/art.38202.
Review
For citations:
Avdeeva A.S., Novikov A.A., Aleksandrova E.N., Karateev D.E., Luchikhina E.L., Nasonov E.L. CHANGES OF CYTOKINE LEVELS DURING THERAPY WITH METHOTREXATE AND ADALIMUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS (REMARCA STUDY). Rheumatology Science and Practice. 2014;52(3):254-262. (In Russ.) https://doi.org/10.14412/1995-4484-2014-254-262
Views:
986
Email this article 